Fewer needles, same safety? new study tests smarter prostate cancer detection.

NCT ID NCT07516223

Recruiting now Diagnosis Sponsor: Shanghai East Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether men with very high PSA and suspicious MRI can safely skip the painful 12-needle systematic biopsy and rely only on targeted samples. Over 1,200 men will get both biopsies, but each sample is analyzed separately to see how often the extra needles find dangerous cancers the targeted ones missed. If the extra needles find less than 5% of cancers, doctors may change guidelines to spare men unnecessary pain, bleeding, and infection risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could prove that many men with high PSA and suspicious MRI can skip the painful 12-needle systematic biopsy, reducing complications and costs.
What could go wrong: This is a diagnostic study, not a treatment trial. It may show that systematic biopsy is still needed for some men, or the 5% threshold might not be met, meaning no change in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pleomorphic adenoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSA PSA PROGRESSION

Contacts and locations

Locations

Shanghai east hospital
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.